Friday, March 25, 2022

< + > Moderna Stock Plunges Despite 'Vaccine Day' Touting 31 New Shots And $21 Billion In Sales—Here's Why

One analyst blasted Moderna's flu vaccine results as a "non-starter" clinically, while others said investors are still too focused on Covid.

No comments:

Post a Comment

< + > Beyond Data Exchange: The Next Era of Interoperability Happens Inside Clinical Workflows

The following is a guest article by Jonathan Shoemaker , CEO at ABOUT Healthcare For a time period that seems like just about forever, the ...